The therapeutic effect of the combination of altplas and ibtifibatide (integrilin) in comparison with altplas (r-TPA) alone, in the treatment of acute ischemic stroke

Study of the therapeutic effect of the combination of altplas and ibtifibatide (integrilin) in comparison with altplas (r-TPA) alone, in the treatment of acute ischemic stroke

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170117032025N9

Enrollment

Registered

2021-04-07

Start date

2021-04-21

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke. Cerebellar stroke syndrome

Interventions

Intervention 1: Intervention group: In the group receiving the combination drug Altplase and Iftifibatide (Integrilin), Altplase ampoule is used only once and the dose of Altplase is 9 tenths of a mil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients should have a serious measurable neurological defect on the NIHSS stroke scale due to focal ischemia of the brain (NIHSS score> 5). Intravenous therapy should be started within 3 hours of the onset of stroke symptoms.

Exclusion criteria

Exclusion criteria: Suspect subarachnoid hemorrhage, even if the brain CT scan is normal

Design outcomes

Primary

Measure	Time frame
Cerebral hemorrhage. Timepoint: Admission, discharge and three months later. Method of measurement: By NIHSS(National Institutes of Health Stroke Scale) criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mahmood Behroozi

Hamedan University of Medical Sciences

behrouzi2012@gmail.com+98 81 3838 0535

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026